Table 3.
Age of subjects and the onset time of thyroid disorder-related symptoms following COVID-19 vaccination according to the gender of patients
| Thyroid disorders | Gender | No (%) | Age, years -mean ± SD Median (min–max) |
Cases with disease onset after 1st dose | Onset time after 1st dose (days) | Cases with disease onset after 2nd dose | Onset time after 2nd dose (days) |
|---|---|---|---|---|---|---|---|
| Subacute thyroiditis | Men | 14 (28.0) |
49.21 ± 15.34 45.5 (26–75) |
10 (71.4%c) |
9.50 ± 4.32a 10 (3–15)b |
4 (28.6%c) |
20.25 ± 12.41a 18.5 (7–37)b |
| Womene | 36 (72.0) |
41.63 ± 10.97 39.5 (26–73) |
19 (52.8%c) |
10.73 ± 6.08 10.0 (3–21) |
16 (44.4%c) |
11.25 ± 10.57 6.5 (0.5–30) |
|
| Total | 50 (100.0) |
43.76 ± 12.65 40 (26–75) |
29 (58.0%d) |
10.31 ± 5.49 10 (3–21) |
20 (40.0%d) |
13.05 ± 11.23 10.5 (0.5–37) |
|
| Graves’ disease | Men | 5 (23.8) |
46.40 ± 15.89 46 (30–70) |
2 (40.0%c) |
14.50 ± 0.70 14.5 (14–15) |
3 (60.0%c) |
19.33 ± 15.01 28.0 (2–28) |
| Women | 16 (76.2) |
49.37 ± 15.44 44 (28–73) |
11 (68.8%c) |
15.18 ± 20.08 7.0 (1–60) |
5 (31.2%c) |
15.60 ± 11.45 14.0 (5–35) |
|
| Total | 21 (100) |
48.66 ± 15.20 46 (28–73) |
13 (61.9%d) |
15.07 ± 18.33 10 (1–60) |
8 (38.1%d) |
17.0 ± 11.96 14.0 (2–35) |
a, b The onset time expressed as mean ± SD and median (min–max), respectively
c, d The percent was calculated within a specified gender and according to the onset time of symptoms, respectively
eThe onset time of symptoms has not been reported for 1 woman with subacute thyroiditis